Enabling Drug Delivery Technologies

1,491 views
1,393 views

Published on

Daniel Ruppar, North American Industry Manager, Pharmaceuticals and Biotechnology Research group at Frost & Sullivan, moderated a panel on drug delivery technologies at a recent BIO International conference.

Published in: Business, Health & Medicine
1 Comment
2 Likes
Statistics
Notes
No Downloads
Views
Total views
1,491
On SlideShare
0
From Embeds
0
Number of Embeds
14
Actions
Shares
0
Downloads
31
Comments
1
Likes
2
Embeds 0
No embeds

No notes for slide
  • Removed essentially in first sentence
  • Only 5% have ever used Exubera, including 2% who are currently using it. Only
  • Fix chart
  • Fixed – was oral
  • Enabling Drug Delivery Technologies

    1. 1. Enabling Drug Delivery Technologies Improving Current Therapies and Helping New Chemical Entities Reach the Market
    2. 2. Panel Discussion <ul><li>Eric Tomlinson, PhD, DSc - President and CEO, Altea Therapeutics </li></ul><ul><li>Riccardo Panicucci, PhD Global Head of Chemical & Pharmaceutical Profiling - Novartis </li></ul><ul><li>Mary Gardner - Director, Technology Assessment, Hospira, Inc. </li></ul><ul><li>Randy Johnson, PhD - Vice President and Chief of Technology Development, KAI Pharmaceuticals </li></ul><ul><li>Bob Baughman, PhD, PharmD - VP Experimental Pharmacology, MannKind Corporation </li></ul><ul><li>Daniel Ruppar – Moderator </li></ul><ul><li>Industry Manager, North America </li></ul><ul><li>Pharmaceuticals & Biotechnology, Frost & Sullivan </li></ul>
    3. 3. Current State of BioPharma <ul><li>The pharmaceutical and biotechnology industry is in a state of transition. </li></ul><ul><li>Reorganization, M&A, consolidation, and portfolio changes are being evaluated in order to maintain growth centers in the face of a myriad of serious challenges. </li></ul><ul><li>Overall, companies are looking to align with areas of growth opportunity as well as new business strategy and product development paradigms. </li></ul><ul><li>Biologics, biogenerics, and drug delivery technologies are some of the areas companies are seeking to provide solutions for future revenues. </li></ul>
    4. 4. Importance of Drug Delivery <ul><li>The use of drug delivery technology applications can result in a multitude of outcomes for drug products </li></ul><ul><li>Enabling of Lifecycle Management scenarios </li></ul><ul><li>Enables use of generic compounds and NCEs in new ways </li></ul><ul><li>Can result in new efficacy outcomes and improved drug profile </li></ul><ul><li>Use with new indication development can spur new revenue opportunities </li></ul>
    5. 5. Drug Delivery Challenges <ul><li>Business Model Evolution </li></ul><ul><li>Capturing Value and Returns </li></ul><ul><li>Differentiation </li></ul><ul><li>Understanding True Commercial Opportunity </li></ul><ul><li>Technology and Reformulation Hurdles </li></ul><ul><li>Partnerships </li></ul>
    6. 6. LCM Example: Exelon Franchise Revenues (Global), 2002-2008 Exelon Patch Launch Source: Frost & Sullivan
    7. 7. Improving Current Therapies
    8. 8. Presented Data Data Collection Methods The study utilized Frost & Sullivan’s web-based survey capability. A structured questionnaire with the appropriate metrics was set-up in web format (GMI-MR software). Appropriate screening questions and quota controls were provided to ensure that only qualified respondents participate in the survey. <ul><li>Sample Structure </li></ul><ul><li>Doctors 206 </li></ul><ul><li>Primary Care Physicians 50 </li></ul><ul><li>Endocrinologists 50 </li></ul><ul><li>Psychiatrists 27 </li></ul><ul><li>Rheumatologists 26 </li></ul><ul><li>Neurologists 28 </li></ul><ul><li>Physical Medicine/ Rehab 10 </li></ul><ul><li>Anesthesiologist / Pain Management 15 </li></ul><ul><li>Patients 450 </li></ul><ul><li>Diabetes 150 </li></ul><ul><li>Chronic Pain 150 </li></ul><ul><li>Inflammation 150 </li></ul>Sample Doctors (206) and patients (450) in the U.S. participated in this survey. The structure of the sample is shown in the table.
    9. 9. Factors Impacting Patient Compliance Efficacy, adverse side effects, ease-of-use, and patient education are perceived by doctors as the most important drivers of patient compliance . How would you categorize the importance of the following factors on patient compliance? MD
    10. 10. Factors for Selecting Drug Delivery Type The top 5 factors considered by a majority (over 50%) of doctors are: minimal side effects, patients’ ease of use, satisfaction, convenience, comfort. Q5. In order of importance, please select the top 5 factors that you consider when selecting a drug delivery type? (1= most important, 2=2 nd most important, 3=3 rd most important, etc.)   MD
    11. 11. Importance of Overall Device in Final Selection to Prescribe The device itself is an important consideration when selecting device-driven drugs. Only 12 percent of doctors consider it as only slightly important or not important at all. For Device Driven Drug Delivery (Examples: Inhaler, Autoinjector) – How important is the overall device in your final selection to prescribe that drug product? MD
    12. 12. Exubera: Satisfaction, Desired Improvements (U.S.), Q4 2007 Q10c) Have you used Exubera? Q10d How satisfied are you with your overall experience using Exubera? Q10e What would you like to change about your usage experience with Exubera? 20% are satisfied with the product. Improvements in the delivery device and a decrease in side effects are most desired . Patient
    13. 13. Byetta: Usage, Satisfaction, Desired Improvements (U.S.), Q4 2007 Q11c Have you used Byetta? Q11d How satisfied are you with your overall experience using Byetta? Q11e What would you like to change about your usage experience with Byetta? 21% have used Byetta, including 13% who are currently using it. 53% of patients are satisfied. Lowering or elimination of side effects and reduction in frequency of dosing are the most desired improvements. Patient
    14. 14. New Opportunities
    15. 15. Attitude Towards New Delivery Forms A majority of respondent doctors are willing to prescribe new drug delivery forms. Forty-one percent adopt new delivery forms earlier than their peers. Thirty-four percent disagree that they are very cautious about prescribing new delivery forms, while an equal proportion would agree to the same statement. Q9. To what extent would you agree or disagree with the following statements, as they apply to your own beliefs and practices? MD
    16. 16. Pulmonary Delivery – Willingness to Use Diabetes Type I Indicate your degree of willingness to use it in the future assuming it is available, affordable, and can be prescribed by your doctor? Patient 31%: Willing To Use 35% Education Gap
    17. 17. From 12 different possible reason statements presented, there were 4 top categories for willing to use pulmonary delivery, the leading being No (or Minimal) Discomfort/Pain. Q2h What is your Top reason for your willingness to use these types of drug delivery in the future for Diabetes Type I? Reasons for Willingness to Use Pulmonary Delivery Diabetes Type I . Patient
    18. 18. Drug Delivery Method – Willingness to Use Diabetes Type II Q2f. For each of the following types of drug delivery, please indicate your degree of willingness to use it in the future for <Disease Type>, assuming all these are available, affordable, and can be prescribed by your doctor About 41% of Diabetes Type 2 patients are willing to use a transdermal patch in the future Education Gap Willing To Use Patient
    19. 19. Currently Unavailable but Desirable Method – Diabetes Transdermal Patch is the most preferred method followed by Pulmonary and Intranasal when all profiled types are considered for new delivery forms by MDs. Q2d. Which drug delivery method (if any) that is currently unavailable, do you think should be made available for the for the treatment of <Disease Type> ? MD
    20. 20. Reasons for Drug Delivery Method to be Made Available - Diabetes Patient convenience, ease-of-use, and satisfaction are the most appealing attributes of transdermal patches. Pulmonary and intranasal methods are both associated with rapid onset of action, though intranasal is more identified with ease of use. What are the top 3 attributes of <method chosen> that make it appealing for the treatment of Diabetes? MD
    21. 21. Drug Delivery Method – Willingness to Use – Chronic Pain Q2f. For each of the following types of drug delivery, please indicate your degree of willingness to use it in the future for <Disease Type>, assuming all these are available, affordable, and can be prescribed by your doctor More than 60 percent of patients are willing/very willing to use a Transdermal patch or a Topical gel/cream for Chronic pain in the future. Patient
    22. 22. Q2h What is your Top reason for your willingness to use these types of drug delivery in the future for <Disease Type>. Easy to self administer is the top reason for willingness to use for most drug delivery methods. Patients are most willing to use use injection or an intravenous infusion due to its rapid onset of drug action. Reasons for Willingness to Use Drug Delivery Methods - Chronic Pain Patient
    23. 23. Panel Discussion
    24. 24. Panel Discussion Points <ul><li>Key Benefits to Developers </li></ul><ul><li>Current Value Within Big Pharma </li></ul><ul><li>Challenges with Reformulation and NCE Usage of DD Tech </li></ul><ul><li>New Opportunities for Developers </li></ul><ul><li>Importance of 360 Degree Draw Factors </li></ul><ul><li>Partnership Benefits </li></ul><ul><li>AFRESA Benefits and Challenges with Peer Failures </li></ul><ul><li>Transdermal Applications in Diabetes </li></ul><ul><li>Economic Environment, New Administration, Health Economics </li></ul><ul><li>Importance of Continued Tech Investment </li></ul><ul><li>Business Model Evolution and Sustainability </li></ul>
    25. 25. <ul><li>To leave a comment or ask the analyst a question, please contact: </li></ul><ul><ul><li>Jake Wengroff </li></ul></ul><ul><ul><li>Global Director, Corporate Communications </li></ul></ul><ul><ul><li>(210) 247- 3806 </li></ul></ul><ul><ul><li>jake.wengroff@frost.com. </li></ul></ul><ul><li>Follow Frost & Sullivan on Twitter </li></ul><ul><li>http://twitter.com/Frost_Sullivan </li></ul>For Additional Information

    ×